GH Research

Yahoo Finance • 6 months ago

GH Research Announces Novel Therapies Symposium Presentation and Posters at the 2025 ECNP Congress

DUBLIN, Oct. 09, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announc... Full story

Yahoo Finance • 8 months ago

GH Research GAAP EPS of -$0.15

* GH Research press release [https://seekingalpha.com/pr/20192823-gh-research-reports-second-quarter-2025-financial-results-and-provides-business-updates] (NASDAQ:GHRS [https://seekingalpha.com/symbol/GHRS]): Q2 GAAP EPS of -$0.15. * C... Full story

Yahoo Finance • 9 months ago

GH Research reports progress on FDA engagement for GH001 IND

DUBLIN - GH Research PLC (NASDAQ:GHRS), a $1.04 billion market cap biotech company that has seen its stock surge 90% over the past six months, reported Wednesday that it continues to engage with the U.S. Food and Drug Administration regard... Full story

Yahoo Finance • 9 months ago

GH Research Announces Global Pivotal Program Plans and Further Development Updates

Engagement with FDA on GH001 IND complete response ongoingThe fully completed Open-Label Extension analysis confirms a 73% remission rate at 6 months with infrequent treatment visits and no psychotherapyTreatment was well tolerated and no... Full story

Yahoo Finance • 9 months ago

GH Research Responds to FDA Clinical Hold on Depression Treatment GH001 Ahead of Schedule

GH Research (NASDAQ:GHRS) is one of the best-performing NASDAQ stocks according to analysts. On June 20, GH Research announced that it had submitted a complete response to the US FDA regarding the clinical hold on its Investigational New D... Full story

Yahoo Finance • 10 months ago

GH Research submits response to FDA clinical hold for depression drug

DUBLIN - GH Research PLC (NASDAQ:GHRS), a $752 million market cap biotech company whose shares have surged 73% over the past six months, announced Friday it has submitted its complete response to the U.S. Food and Drug Administration regar... Full story

Yahoo Finance • 10 months ago

GH Research Submits Complete IND Hold Response to FDA Ahead of Schedule

DUBLIN, June 20, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announc... Full story

Yahoo Finance • last year

GH Research Reports Full Year 2024 Financial Results and Provides Business Updates

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025Phase 1 clinical trial to evaluate proprietary aerosol delivery device in... Full story

Yahoo Finance • last year

GH Research Announces Pricing of $150 Million Public Offering

DUBLIN, Feb. 05, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announc... Full story

Yahoo Finance • last year

GH Research Announces Proposed Public Offering

DUBLIN, Feb. 03, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announc... Full story

Yahoo Finance • last year

GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction

Primary endpoint met, GH001 led to an ultra-rapid anti-depressant effect with a significant placebo-adjusted MADRS reduction from baseline of -15.5 on Day 8 (p<0.0001)The majority of the patients treated with GH001 achieved remission with... Full story

Yahoo Finance • last year

GH Research to Provide Update on Phase 2b Trial with GH001 in TRD

DUBLIN, Jan. 31, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced that it will host a c... Full story

Yahoo Finance • 2 years ago

15 Best Falling Stocks To Buy Now

In this article, we will take a detailed look at the15 Best Falling Stocks To Buy Now. For a quick overview of such stocks, read our article 5Best Falling Stocks To Buy Now. The Wall Street is headed to end 2023 on a strongly positive not... Full story

Yahoo Finance • 2 years ago

GH Research Reports Third Quarter Financial Results and Provides Business Updates

DUBLIN, Ireland, Nov. 09, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial res... Full story

Yahoo Finance • 3 years ago

GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression

DUBLIN, Ireland, Sept. 29, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today provided updates and... Full story

Yahoo Finance • 3 years ago

GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates

DUBLIN, Ireland, Aug. 23, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial res... Full story

Yahoo Finance • 3 years ago

10 Best Psychedelic Stocks to Buy According to Hedge Funds

In this article, we discuss 10 best psychedelic stocks to buy according to hedge funds. If you want to see more stocks in this selection, check out 5 Best Psychedelic Stocks to Buy According to Hedge Funds. Data Bridge Market Research pre... Full story

Yahoo Finance • 3 years ago

GH Research Reports Full Year 2022 Financial Results and Provides Business Updates

DUBLIN, Ireland, March 02, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial re... Full story

Yahoo Finance • 3 years ago

GH Research Reports Third Quarter 2022 Financial Results and Provides Business Updates

DUBLIN, Ireland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial res... Full story

Yahoo Finance • 4 years ago

GH Research Reports Second Quarter 2022 Financial Results and Provides Business Updates

DUBLIN, Ireland, Aug. 23, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial res... Full story